Search
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnwhere the drug had been approved. … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Yohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnYohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-2 Receptor AntagonistsHydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedIt has the smell of lilac, lily, and lily of the valley [A34269]. … Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine may be used in alone or in combination with other agents in the management of hypertension. … By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.
International brands: Ji Ni Le ErPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigational[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. … [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsAminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalOnce in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. … The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.
Categories: Purinergic P1 Receptor AntagonistsIndomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigational[A177871] Since then, indometacin has been extensively studied in clinical trials as one of the most potent NSAIDs in blocking prostaglandin synthesis and was among the first NSAIDs to be used in the symptomatic … [A177871] The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is
Lenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigationalHIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens … [L42995] On December 22, 2022, it was also approved by the FDA.[L44473]
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. … In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects.
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. … Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Categories: Serotonin Receptor Antagonists, Dopamine D2 Receptor Antagonists